Compare ADP & BSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADP | BSX |
|---|---|---|
| Founded | 1949 | 1979 |
| Country | United States | United States |
| Employees | N/A | 59000 |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.2B | 65.8B |
| IPO Year | 2005 | 2010 |
| Metric | ADP | BSX |
|---|---|---|
| Price | $250.40 | $44.36 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 22 |
| Target Price | ★ $275.57 | $93.18 |
| AVG Volume (30 Days) | 2.2M | ★ 17.2M |
| Earning Date | 04-29-2026 | 04-22-2026 |
| Dividend Yield | ★ 3.16% | N/A |
| EPS Growth | 9.67 | ★ 55.20 |
| EPS | ★ 8.49 | 0.90 |
| Revenue | ★ $20,560,900,000.00 | $9,076,000,000.00 |
| Revenue This Year | $7.08 | $11.85 |
| Revenue Next Year | $5.69 | $10.16 |
| P/E Ratio | ★ $28.61 | $48.42 |
| Revenue Growth | 7.07 | ★ 12.49 |
| 52 Week Low | $188.16 | $42.20 |
| 52 Week High | $315.92 | $109.50 |
| Indicator | ADP | BSX |
|---|---|---|
| Relative Strength Index (RSI) | 60.77 | 46.85 |
| Support Level | $249.50 | $42.23 |
| Resistance Level | $265.75 | $46.37 |
| Average True Range (ATR) | 5.99 | 1.17 |
| MACD | -0.51 | 0.29 |
| Stochastic Oscillator | 58.69 | 55.04 |
Automatic Data Processing, or ADP, is a global, cloud-based human capital management provider offering payroll, compliance, talent management, benefits administration, and retirement services. The firm also provides HR outsourcing services, including PEO offerings, enabling clients to reduce HR overhead. Its broad suite serves customers of all sizes across diverse sectors, and the firm holds large market shares in its core markets. As of fiscal 2025, ADP counts over 1.1 million clients and manages payroll for more than 42 million workers across 140 countries.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.